Phase I trial shows positive results for stem cell treatment

A team led by researchers from Mass Eye and Ear, a member of Mass General Brigham, reports the results of a phase I trial of a revolutionary stem cell treatment called cultivated autologous limbal epithelial cell transplantation (CALEC), which was found to be safe and well-tolerated over the short term in four patients with significant chemical burns in one eye.

Related Keywords

Dana Farber Cancer Institute , Massachusetts , United States , Boston , Danielle Ellis , Heather Daley , Myriam Armant , Jerome Ritz , Lassana Samarakoon , Sanming Li , Alex Gauthier , Ahmad Kheirkhah , Maureen Maguire , Stacey Ellender , Lynette Johns , Ula Jurkunas , Reza Dana , Kishore Katikireddy , Diegoe Hernandez Rodriguez , Allison Ayala , National Eye Institute , Cell Therapy Institute , Jaeb Center , National Heart , Blood Institute , Drug Administration , National Institutes Of Health , Cornea Service At Mass Eye , Health Research , Harvard Medical School , Mass Eye , Mass General Brigham , Science Advances , Cornea Service , Harvard Medical , O Reilly Families Cell Manipulation Core Facility , Dana Farber Cancer , Boston Children , National Institutes , General Brigham , Jia Yin , Stephan Ong Tone , Cell , Gornea , Stem Cells , Biopsy , Dancer , Children , Clinical Trial , Ear , Eye , Hospital , Manufacturing , Medical School , Neck , Ophthalmology , Rain , Quality Control , Research , Throat , Transplant , Vision Loss ,